Patents by Inventor Olivier Lantz

Olivier Lantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230322952
    Abstract: The invention provides a multispecific molecule capable of simultaneous binding to a Mucosal Associated Invariant T (MAIT) cell and a tumor cell, which multispecific molecule comprises at least one domain that specifically binds a V?7.2 T cell receptor (TCR) and at least one domain that specifically binds a tumor associated antigen (TAA).
    Type: Application
    Filed: January 8, 2021
    Publication date: October 12, 2023
    Inventors: OLIVIER LANTZ, SEBASTIAN AMIGORENA, MICHAEL SAITAKIS, MAUDE GUILLOT-DELOST, EUGENE ZHUKOVSKY, PIERRE-EMMANUEL GERARD, MUSTAPHA FAROUDI
  • Publication number: 20230212243
    Abstract: The present application relates to a tumor specific neoantigenic peptide, wherein said peptide is encoded by a part of an ORF sequence from a transcript associated with a SF3B1 or a SF3B1-like mutation, comprises at least 8 amino acids and binds at least one MHC molecule with an affinity of less than 500 nM; and is not expressed in normal healthy cells. The present application further relates to vaccine or immunogenic composition, antibodies, T cell receptors, polynucleotides, vectors and immune cells derived thereof as well as their use in therapy of cancer.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 6, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Olivier Lantz, Marc-Henri Stern, Jérémy Bigot, Alexandre Houy, Ana Ines Lalanne
  • Publication number: 20220065849
    Abstract: A method for identifying cognate pairs of a ligand species and a receptor species includes co-compartmentalizing ligand species and receptor species, forming a set of microreactors, each microreactor including a ligand species and preferably a receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when a ligand species and receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 3, 2022
    Inventors: Andrew GRIFFITHS, Sebastien AMIGORENA, Olivier LANTZ, David WEITZ, Philippe NGHE, Annabelle GERARD
  • Publication number: 20220016171
    Abstract: The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. More specifically, the invention relates to Mucosal-Associated Invariant T (MAIT) cells expressing Chimeric Antigen Receptors (CARs), wherein the MAIT cell is allogenic with respect to the subject to be treated.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Olivier LANTZ, Sophie CAILLAT-ZUCMAN
  • Patent number: 7829289
    Abstract: The invention relates to methods of modulating an immune response in a mammal by modulating the activity of J?33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising J?33 T cells, MR1 polypeptide or a compound that modulates the activity of J?33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said J?33 T cells or MR1 polypeptide.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: November 9, 2010
    Assignees: Institut National de la Sante et de Recherche Medicale, Institut Curie
    Inventors: Olivier Lantz, Emmanuel Treiner
  • Publication number: 20030215808
    Abstract: The invention relates to methods of modulating an immune response in a mammal by modulating the activity of J&agr;33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising J&agr;33 T cells, MR1 polypeptide or a compound that modulates the activity of J&agr;33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said J&agr;33 T cells or MR1 polypeptide.
    Type: Application
    Filed: May 14, 2002
    Publication date: November 20, 2003
    Inventors: Olivier Lantz, Emmanuel Treiner